Printer Friendly

THE LIPOSOME COMPANY ANNOUNCES NEW EXECUTIVE DIRECTOR OF BIOLOGICAL SCIENCES

 THE LIPOSOME COMPANY ANNOUNCES NEW EXECUTIVE DIRECTOR
 OF BIOLOGICAL SCIENCES
 PRINCETON, N.J., Jan. 6 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) announced today that it has appointed Karl E. Arfors to the newly created position of executive director of biological sciences. Dr. Arfors will direct the company's biological research efforts focusing on the development of rationally designed drugs targeted to the treatment of diseases whose etiologies lie in the cells of the vasculature.
 Dr. Arfors has had an extensive career in biological research in the pharmaceutical industry, most recently as president and CEO of the La Jolla Institute for Experimental Medicine and director of explorative research, Pharmacia Experimental Medicine, in La Jolla. He has headed major research programs into the mechanisms of cell adhesion, microcirculation and inflammation.
 Among Dr. Arfors' many scientific accomplishments is the discovery of one of the major mechanisms involved in cell adhesion in vivo. His teams identified "rolling and sticking," the way neutrophils and endothelial cells adhere to each other as a precursor to acute inflammation. Neutrophils are a type of white blood cells. Endothelial cells line the blood vessels. Dr. Arfors described the way neutrophils first "roll" along the blood vessel lining before "sticking" to endothelial cells. Once the cells adhere to each other, various chemicals are released that can cause a number of acute inflammatory conditions, including Adult Respiratory Distress Syndrome (ARDS), septic shock, reperfusion injury following heart attacks, and others. It is believed that prevention of this "rolling and sticking" could prevent or treat these inflammatory conditions.
 At The Liposome Company, Dr. Arfors will direct the company's biological research efforts focusing on the development of rationally designed drugs targeted to cells within the vasculature. The company's TLC C-53, a liposomal prostaglandin E1, is currently being developed as a cell adhesion antagonist for the treatment of acute inflammatory conditions. Dr. Arfors' mission will include further elucidation of TLC C-53's mechanism of action, but his main focus will be on the discovery of novel therapeutics for the treatment of diseases originating in the cells of the blood's circulation.
 "The addition of Dr. Arfors represents the next logical step in our long-term research and drug discovery program and marks the beginning of a new era for The Liposome Company," said Charles A. Baker, chairman and chief executive officer of The Liposome Company. "We believe we have in place the world's leading lipid and liposomal drug research and development team. With TLC C-53 and our recently acquired technology for liposomal fibrinolytic agents, we are building a strong pipeline of products targeted to diseases of the cells of the vasculature. Now with the addition of Dr. Arfors, we are in a unique position to mount a rational, targeted approach to modifying the vascular cell processes that lead to a wide variety of life threatening and disabling diseases."
 Dr. Arfors has published over 200 scientific papers. He is a member of numerous scientific organizations and is a frequent speaker at biological meetings. The 55-year-old scientist is married and will relocate to the Princeton, N.J., area.
 The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment and diagnosis of life-threatening illnesses.
 -0- 1/6/92
 /CONTACT: Anne Van Lent, senior vice president and chief financial officer of the Liposome Company, 609-452-7060/
 (LIPO) CO: The Liposome Company ST: New Jersey IN: MTC SU: PER


PS -- NY006 -- 6762 01/06/92 09:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1992
Words:578
Previous Article:EQUIMARK ANNOUNCES PROJECTED EARNINGS
Next Article:CIRCUIT CITY STORES, INC. REPORTS DECEMBER SALES
Topics:


Related Articles
THE LIPOSOME COMPANY REPRESENTS AT THE HAMBRECHT & QUIST LIFE SCIENCES CONFERENCE
THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK
WYETH-AYERST RETURNS VACCINE ADJUVANT RIGHTS
RESEARCHERS FIND A KEY TO PROSTAGLANDIN PARADOX; BREAKTHROUGH OFFERS NEW APPROACH TO TREATING INFLAMMATORY DISEASES
THE LIPOSOME COMPANY, INC. REPORTS MORE THAN $6 MILLION IN SALES OF ABELCET IN THE FIRST 8 WEEKS OF 1996
THE LIPOSOME COMPANY RECORDS $10 MILLION IN FIRST QUARTER ABELCET SALES
THE LIPOSOME COMPANY, INC. ANNOUNCES ORGANIZATIONAL CHANGE
LIPOSOME COMPANY PATENT UPHELD BY PATENT OFFICE
THE LIPOSOME COMPANY ADOPTS SHAREHOLDER RIGHTS PLAN
The Liposome Company Declares Quarterly Dividend On Preferred Stock

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters